Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IR (Immediate-Release) quetiapine fumarate (drug)
IR quetiapine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| IR (Immediate-Release) quetiapine fumarate (drug) | DRUG | - |
Inclusion Criteria: * Men and women age ≥18 to ≤65 years with acute schizophrenia * Provision of written informed consent prior to enrolment Exclusion Criteria: * Meeting the criteria for any other (than schizophrenia) psychotic disorder not in full remission, concomitant organic mental disorder ...
Top 15 of 16 competitors
IR quetiapine is an immediate-release formulation of quetiapine fumarate, a small molecule developed by AstraZeneca PLC (ticker AZN). It has been studied in schizophrenia, a psychiatric condition, and is identified in clinical research as IR (Immediate-Release) quetiapine fumarate.
IR quetiapine has been studied for the treatment of schizophrenia. AstraZeneca PLC evaluated it in a Phase 2 trial of acute schizophrenic patients, comparing rapid dose escalation with conventional escalation. The trial enrolled 30 participants aged 18 years and older in Germany.
IR quetiapine is developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the clinical research evaluating this immediate-release quetiapine fumarate formulation in schizophrenia.
IR quetiapine is in Phase 2 clinical development for schizophrenia. It is investigational and has been studied in one completed Phase 2 trial. No active trials are currently listed for this asset.
IR quetiapine has been studied in one completed Phase 2 trial, NCT00254787, titled Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients. The randomized, double-blind trial enrolled 30 participants in Germany, with no healthy volunteers and no biomarker selection.
Yes, IR quetiapine is the same as IR (Immediate-Release) quetiapine fumarate. The abbreviation IR stands for immediate-release, referring to the formulation of quetiapine fumarate developed by AstraZeneca PLC. Both names refer to the same small molecule studied in schizophrenia.